Dulaglutide
- Generic Name
- Dulaglutide
- Brand Names
- Trulicity
- Drug Type
- Biotech
- CAS Number
- 923950-08-7
- Unique Ingredient Identifier
- WTT295HSY5
- Background
Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.
- Indication
Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 807
- Registration Number
- NCT01126580
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nottingham, United Kingdom
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 810
- Registration Number
- NCT01075282
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yung-Kang, Tainan, Taiwan
A Study in Participants With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 978
- Registration Number
- NCT01064687
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yabucoa, Puerto Rico
A Study of LY2189265 in Japanese Patients With Type 2 Diabetes
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 145
- Registration Number
- NCT01001104
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1202
- Registration Number
- NCT00734474
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yung-Kang, Tainan, Taiwan
A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 262
- Registration Number
- NCT00630825
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toa Baja, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.